Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px
Document › Details

Noxxon Pharma N.V.. (10/24/16). "Press Release: Noxxon Pharma Announces the Implementation of a Liquidity Contract with Invest Securities". Berlin.

Organisations Organisation Noxxon Pharma N.V. (Alternext Paris: ALNOX)
  Group Noxxon (Group)
  Organisation 2 Invest Securities S.A.
Products Product Spiegelmer® technology
  Product 2 financial services
     


NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that the company entrusts Invest Securities with the implementation of a liquidity contract in accordance with the Charter of Ethics established by the Association française des marchés financiers (AMAFI) on 8 March 2011 and the decision of the Autorité des marchés financiers (AMF) on 21 March 2011.

For the implementation of this contract, the following resources have been allocated to the liquidity account:

> €100 000 (one hundred thousand euros)
> 10 000 (ten thousand) shares


About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

   
Record changed: 2017-01-13

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for Noxxon (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2017 Germany May 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2017 Germany May 120x80px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture Berlin Partner HealthCapital Bionnale 2017 Germany May 120x80px